Immunic, Inc. (IMUX) Income Statement
IMUX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIMUX revenue and net income
IMUX profit margins
IMUX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IMUX quarterly EPS vs estimates
Immunic beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.82).
IMUX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $6,000 |
| Cost of revenue | $168,000 | $134,000 | $111,000 | $77,000 | $85,000 | $39,000 | $50,000 | $15,000 | $998,000 | $206 |
| Gross profit | −$168,000 | −$134,000 | −$111,000 | −$77,000 | −$85,000 | −$39,000 | −$50,000 | −$15,000 | −$998,000 | $5,794 |
| Research & development | $82.0M | $80.0M | $83.2M | $71.3M | $61.1M | $38.6M | $22.5M | $24.8M | $39.3M | $30.0M |
| Sales, general & admin | $21.2M | $18.0M | $16.1M | $15.3M | $13.3M | $10.3M | $14.5M | $13.6M | $13.3M | $11.2M |
| Total operating expenses | $103.2M | $98.1M | $99.2M | $119.5M | $91.7M | $49.0M | $37.0M | $38.4M | $52.7M | $41.3M |
| Operating income | −$103.2M | −$98.1M | −$99.2M | −$119.5M | −$91.7M | −$49.0M | −$37.0M | −$42.0M | −$52.7M | −$41.3M |
| Interest income | $1.0M | $3.4M | $3.1M | $1.0M | $66,000 | $58,000 | $107,000 | $521,000 | $650,000 | $284,000 |
| Interest expense | — | — | — | $1.0M | $85,000 | $58,000 | $107,000 | $0 | $0 | $0 |
| Income before taxes | −$97.2M | −$100.5M | −$93.6M | −$120.4M | −$92.9M | −$44.0M | −$34.9M | −$41.5M | −$52.1M | −$41.0M |
| Income taxes | — | −$100.5M | — | $33.9M | −$151,000 | −$58,000 | −$107,000 | $549,000 | −$577,000 | −$1.8M |
| Net income | −$97.2M | −$100.5M | −$93.6M | −$120.4M | −$92.8M | −$44.0M | −$34.8M | −$41.5M | −$52.1M | −$41.0M |
| EBITDA | −$97.0M | −$100.4M | −$93.5M | −$86.4M | −$91.6M | −$48.9M | −$37.0M | −$14.4M | −$51.1M | −$39.5M |
| EPS (diluted) | −$1.87 | −$10.00 | −$16.78 | −$27.38 | −$24.66 | −$17.25 | −$31.80 | −$39.20 | −$53.20 | −$52.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | 96.6% |
| Operating margin | — | — | — | — | — | — | — | — | — | −687,766.7% |
| Net margin | — | — | — | — | — | — | — | — | — | −682,816.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $114,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $33,000 | $42,000 | — | $43,000 | $43,000 | $35,000 | $42,000 | $31,000 | $26,000 | $23,000 | $34,000 |
| Gross profit | — | −$33,000 | −$42,000 | — | −$43,000 | −$43,000 | −$35,000 | −$42,000 | −$31,000 | −$26,000 | −$23,000 | −$34,000 |
| Research & development | $25.9M | $25.6M | $19.1M | $20.0M | $21.4M | $21.5M | $21.6M | $21.4M | $18.3M | $18.7M | $19.3M | $19.8M |
| Sales, general & admin | $9.4M | $7.6M | $4.3M | $6.0M | $5.7M | $5.3M | $4.1M | $4.4M | $4.5M | $5.2M | $4.1M | $3.8M |
| Total operating expenses | $35.3M | $33.2M | $23.3M | $26.0M | $27.1M | $26.8M | $25.6M | $25.7M | $22.8M | $23.9M | $23.4M | $23.6M |
| Operating income | −$35.3M | −$33.2M | −$23.3M | −$26.0M | −$27.1M | −$26.8M | −$25.6M | −$25.7M | −$22.8M | −$23.9M | −$23.4M | −$23.6M |
| Interest income | $1.3M | $760,000 | $197,000 | $419,000 | $241,000 | $183,000 | $429,000 | $776,000 | $998,000 | $1.2M | $541,000 | $766,000 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $2.0M | — |
| Income before taxes | −$34.1M | −$32.6M | −$19.3M | −$25.6M | −$26.8M | −$25.5M | −$25.2M | −$24.4M | −$21.4M | −$29.6M | −$21.6M | −$22.8M |
| Income taxes | — | — | — | — | — | — | $17,276 | — | — | −$17,276 | $3.7M | −$766,000 |
| Net income | −$34.1M | −$32.6M | −$19.3M | −$25.6M | −$26.8M | −$25.5M | −$25.2M | −$24.4M | −$21.4M | −$29.6M | −$21.6M | −$22.8M |
| EBITDA | −$34.1M | −$32.6M | −$19.3M | −$25.5M | −$26.8M | −$25.4M | −$25.1M | −$24.3M | −$21.3M | −$29.6M | −$21.5M | −$22.7M |
| EPS (diluted) | −$0.80 | −$1.08 | −$0.12 | −$1.30 | −$0.20 | −$0.25 | −$2.50 | −$2.40 | −$2.10 | −$3.00 | −$0.48 | −$5.10 |
| Gross margin | — | — | — | — | — | — | −30.7% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −22,483.3% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −22,083.3% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IMUX's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IMUX financial results
Immunic reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $97.2 million. Diluted earnings per share came to −$1.87.
See the IMUX stock overview for the latest quote and news, or the IMUX chart for price history and technical indicators.
IMUX income statement FAQ
Does Immunic have revenue?
Immunic reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Immunic profitable?
No. Immunic reported a net loss of $97.2 million in fiscal 2025.
How much does Immunic spend on research and development?
Immunic spent $82.0 million on research and development in fiscal 2025.
What are Immunic's earnings per share?
Immunic earned $-1.87 per diluted share in fiscal 2025, compared with $-10.00 a year earlier.
When will Immunic report its next earnings?
Immunic is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does Immunic's fiscal year end?
Immunic's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.